tiprankstipranks
Cytokinetics (CH:KK3A)
:KK3A
Switzerland Market
KK3A
Cytokinetics
RESEARCH TOOLSreports

Cytokinetics (KK3A) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

KK3A Analyst Ratings

Strong Buy
17Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Cytokinetics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KK3A Stock 12 Month Forecast

Average Price Target

―
Based on 17 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is CHF90.03 with a high forecast of CHF117.57 and a low forecast of CHF68.45. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF117.57Average Price TargetCHF90.03Lowest Price TargetCHF68.45
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:KK3A
Emily Field
Barclays
Barclays
CHF88.58
Buy
―
Reiterated
08/26/26
Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Summit Therapeutics (SMMT)
J.P. Morgan Analyst forecast on CH:KK3A
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Cytokinetics (NASDAQ: CYTK)
H.C. Wainwright Analyst forecast on CH:KK3A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF112.73
Buy
―
Reiterated
08/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bank of America Securities Analyst forecast on CH:KK3A
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF68.45
Hold
―
Reiterated
08/14/26
Hold Rating Reaffirmed as Patent Dispute Adds Risk; $85 Price Target Remains Unchanged
Truist Financial Analyst forecast on CH:KK3A
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF90.19
Buy
―
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Cytokinetics (CYTK)
Piper Sandler Analyst forecast on CH:KK3A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF86.16
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)
RBC Capital Analyst forecast on CH:KK3A
Leonid Timashev
RBC Capital
RBC Capital
CHF94.21→CHF90.19
Buy
―
Reiterated
08/07/26
Cytokinetics (CYTK) Gets a Buy from RBC Capital
Evercore ISI Analyst forecast on CH:KK3A
Cory Kasimov
Evercore ISI
Evercore ISI
CHF80.52
Buy
―
Reiterated
08/07/26
Cytokinetics (CYTK) Gets a Buy from Evercore ISI
Citizens JMP Analyst forecast on CH:KK3A
Jason Butler
Citizens JMP
Citizens JMP
CHF84.55→CHF88.58
Buy
―
Reiterated
08/07/26
Cytokinetics price target raised to $110 from $105 at CitizensCytokinetics price target raised to $110 from $105 at Citizens
Needham Analyst forecast on CH:KK3A
Serge Belanger
Needham
Needham
CHF82.13→CHF90.19
Buy
―
Reiterated
08/07/26
Cytokinetics (CYTK) Receives a Buy from Needham
Goldman Sachs Analyst forecast on CH:KK3A
Paul Choi
Goldman Sachs
Goldman Sachs
―
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Immunocore Holdings (NASDAQ: IMCR)
Stifel Nicolaus Analyst forecast on CH:KK3A
James Condulis
Stifel Nicolaus
Stifel Nicolaus
CHF86.97
Buy
―
Reiterated
08/07/26
Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)
B. Riley Securities Analyst forecast on CH:KK3A
Mayank Mamtani
B. Riley Securities
B. Riley Securities
CHF117.57
Buy
―
Reiterated
07/31/26
B. Riley Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
Morgan Stanley Analyst forecast on CH:KK3A
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF82.94
Buy
―
Assigned
07/23/26
Cytokinetics (CYTK) Receives a Buy from Morgan Stanley
Citi Analyst forecast on CH:KK3A
Eric Joseph
Citi
Citi
CHF79.72
Buy
―
Reiterated
07/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:KK3A
Emily Field
Barclays
Barclays
CHF88.58
Buy
―
Reiterated
08/26/26
Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Summit Therapeutics (SMMT)
J.P. Morgan Analyst forecast on CH:KK3A
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Cytokinetics (NASDAQ: CYTK)
H.C. Wainwright Analyst forecast on CH:KK3A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF112.73
Buy
―
Reiterated
08/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bank of America Securities Analyst forecast on CH:KK3A
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF68.45
Hold
―
Reiterated
08/14/26
Hold Rating Reaffirmed as Patent Dispute Adds Risk; $85 Price Target Remains Unchanged
Truist Financial Analyst forecast on CH:KK3A
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF90.19
Buy
―
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Cytokinetics (CYTK)
Piper Sandler Analyst forecast on CH:KK3A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF86.16
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)
RBC Capital Analyst forecast on CH:KK3A
Leonid Timashev
RBC Capital
RBC Capital
CHF94.21→CHF90.19
Buy
―
Reiterated
08/07/26
Cytokinetics (CYTK) Gets a Buy from RBC Capital
Evercore ISI Analyst forecast on CH:KK3A
Cory Kasimov
Evercore ISI
Evercore ISI
CHF80.52
Buy
―
Reiterated
08/07/26
Cytokinetics (CYTK) Gets a Buy from Evercore ISI
Citizens JMP Analyst forecast on CH:KK3A
Jason Butler
Citizens JMP
Citizens JMP
CHF84.55→CHF88.58
Buy
―
Reiterated
08/07/26
Cytokinetics price target raised to $110 from $105 at CitizensCytokinetics price target raised to $110 from $105 at Citizens
Needham Analyst forecast on CH:KK3A
Serge Belanger
Needham
Needham
CHF82.13→CHF90.19
Buy
―
Reiterated
08/07/26
Cytokinetics (CYTK) Receives a Buy from Needham
Goldman Sachs Analyst forecast on CH:KK3A
Paul Choi
Goldman Sachs
Goldman Sachs
―
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Immunocore Holdings (NASDAQ: IMCR)
Stifel Nicolaus Analyst forecast on CH:KK3A
James Condulis
Stifel Nicolaus
Stifel Nicolaus
CHF86.97
Buy
―
Reiterated
08/07/26
Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)
B. Riley Securities Analyst forecast on CH:KK3A
Mayank Mamtani
B. Riley Securities
B. Riley Securities
CHF117.57
Buy
―
Reiterated
07/31/26
B. Riley Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
Morgan Stanley Analyst forecast on CH:KK3A
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF82.94
Buy
―
Assigned
07/23/26
Cytokinetics (CYTK) Receives a Buy from Morgan Stanley
Citi Analyst forecast on CH:KK3A
Eric Joseph
Citi
Citi
CHF79.72
Buy
―
Reiterated
07/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

3 Months
Tessa RomeroJ.P. Morgan
Success Rate
17/25 ratings generated profit
68%
Average Return
+25.18%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 68.00% of your transactions generating a profit, with an average return of +25.18% per trade.
1 Year
Joseph PantginisH.C. Wainwright
Success Rate
17/18 ratings generated profit
94%
Average Return
+46.96%
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +46.96% per trade.
2 Years
Joseph PantginisH.C. Wainwright
Success Rate
17/18 ratings generated profit
94%
Average Return
+59.12%
Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 94.44% of your transactions generating a profit, with an average return of +59.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KK3A Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
12
10
4
5
4
Buy
20
20
24
22
24
Hold
7
6
4
3
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
36
32
30
32
In the current month, KK3A has received 28 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. KK3A average Analyst price target in the past 3 months is 90.03.
Each month's total comprises the sum of three months' worth of ratings.

KK3A Financial Forecast

KK3A Earnings Forecast

Next quarter’s earnings estimate for KK3A is -CHF1.18 with a range of -CHF1.34 to -CHF0.89. The previous quarter’s EPS was -CHF1.22. KK3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.
Next quarter’s earnings estimate for KK3A is -CHF1.18 with a range of -CHF1.34 to -CHF0.89. The previous quarter’s EPS was -CHF1.22. KK3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.

KK3A Sales Forecast

Next quarter’s sales forecast for KK3A is CHF32.28M with a range of CHF22.43M to CHF41.71M. The previous quarter’s sales results were CHF23.24M. KK3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.
Next quarter’s sales forecast for KK3A is CHF32.28M with a range of CHF22.43M to CHF41.71M. The previous quarter’s sales results were CHF23.24M. KK3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.

KK3A Stock Forecast FAQ

What is CH:KK3A’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is 90.03.
    What is CH:KK3A’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:KK3A, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Cytokinetics a Buy, Sell or Hold?
        Cytokinetics has a consensus rating of Strong Buy, which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Cytokinetics’s share price target?
          The average share price target for Cytokinetics is 90.03. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF117.57 ,and the lowest forecast is CHF68.45. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Cytokinetics?
            Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
              How can I buy shares of Cytokinetics?
              To buy shares of CH:KK3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.